Trevi Therapeutics (TRVI) reported a third-quarter loss of $0.13 per share, exactly matching the consensus estimate. That was a 62.5% year-over-year deterioration from the $0.08 loss a year earlier, and the clinical-stage company again reported no revenue. For a pre-commercial drug developer, the in-line loss matters less than what changed in the development plan. The central tension is that the competitive and regulatory picture for Haduvio improved, while the timelines and the scope of what Trevi's cash is expected to fund moved the wrong way.

The wider loss reflects a company running a much larger clinical program. Net loss rose to $21.5 million from $11.8 million. R&D expenses nearly doubled to $19.1 million from $10.1 million as the Phase 3 OCEAN-1, Phase 3 OCEAN-2 and Phase 2b LAKE trials ramped. G&A rose to $5.4 million from $3.8 million, driven by stock-based compensation and personnel costs. Interest income on a larger cash balance lifted other income to $3.0 million, which softened the loss only modestly.

The weighted share count climbed to 159.7 million from 145.1 million, reflecting the equity financing that lifted stockholders' equity from $183 million at year-end to $303 million. Cash and marketable securities ended at $299.4 million, down from roughly $319 million at the end of the second quarter. That implies a quarterly burn of about $20 million, which will rise as all three trials enroll in parallel.

The call kept the IPF story intact.

• **OCEAN-2:** The 12-week trial began in the third quarter, with topline data expected in the second half of 2027.
• **OCEAN-1:** The 52-week trial is guided to read out in the first half of 2028.
• **Regulatory status:** Both OCEAN trials are now approved by regulators in all participating countries.

The softer news sits around the edges. The LAKE sample size re-estimation in refractory chronic cough slipped from the fourth quarter of 2026 to early in the first quarter of 2027, although full topline data remain on track for the second half of 2027. The non-IPF ILD program changed more materially. After its October FDA meeting, Trevi described overall alignment on a development path. However, the plan shifted from an adaptive Phase 2/3 study starting in the second half of 2026 to a standalone Phase 2 dose-ranging trial. That trial is expected to enroll roughly 120 patients, start in the first quarter of 2027 and report topline data in the first half of 2028, with a separate Phase 3 likely to follow. Management framed this as regulatory clarity, but it adds a step and pushes eventual approval in that indication further out.

The runway disclosure needs a careful read. Trevi still guides to cash lasting into 2030 and funding IPF-related chronic cough through potential FDA approval. The non-IPF ILD program, however, is now funded only through Phase 2, versus through Phase 3 on the prior call. The headline runway did not shrink, but the work it covers did. A future raise to fund that second Phase 3 is now more explicitly part of the picture.

The offsets are real. Management pointed out that GSK's camlipixant and another Phase 2b program failed, leaving no active competitive programs in refractory chronic cough or Trevi's other targeted cough indications. A Notice of Allowance for a patent covering dosing in hepatically impaired non-IPF ILD patients would extend protection to 2041, versus 2039 for the base patents. A patient-focused drug development meeting with the FDA, with a Voice of the Patient report due in 2027, could raise the profile of chronic cough as an unmet need. Bears still have legitimate ammunition:

• questions about the size and durability of the refractory chronic cough market;
• concern that payer pricing in that broad population could cannibalize pricing in IPF and ILD;
• the heterogeneity of a non-IPF ILD population spanning more than 100 conditions, which could muddy dose-response.

Investors were already souring before the release. Earnings Whispers sentiment fell sharply, from -0.45 to -0.84, a meaningful move deeper into negative territory. The stock tells a similar story. Shares entered the report at $14.33, down 25.6% since the open after the August report and 25.8% below the August 19 inter-earnings high of $19.30. They have, however, rebounded 22.5% from the October 16 low of $11.70 and are sitting almost exactly on the 200-day moving average of $14.40. Most Earnings Whispers trend readings remain negative, although momentum has turned positive alongside that bounce off the low.

The bottom line is that Trevi delivered an in-line quarter with spending rising as expected, and its competitive position arguably improved as rival programs failed. Still, slipping timelines, an extra Phase 3 step in non-IPF ILD and a narrower funded scope give skeptics something concrete to point to. With sentiment deeply negative and shares hovering at their 200-day average, the near-term setup hinges on the early-2027 LAKE re-estimation and on whether the OCEAN trials enroll on schedule toward the second-half 2027 OCEAN-2 readout.